OBJECTIVES: DAA treatments in addition to Ribavirin (RBV) and peginterferon (Peg-INF) (PR), provides the greatest opportunity to fully achieve sustained virological response (SVR) in HCV infected patients. Currently, two alternatives of DAA, telaprevir (TVR) and boceprevir (BOC), are available in Peru.  The objective of this study is to assess: which is the most efficient DAA treatment to compliment the PR in previously treated patients METHODS: A Markov model was used from the payer perspective to estimate costs and benefits throughout the whole life. Transition probabilities, utilities and resources usage were obtained from literature and through a mixed treatment comparison. Only direct costs were considered as medications, laboratory tests, complications costs and adverse events by using tariffs and tender prices from EsSalud. Outcomes were measured as SVR, quality adjusted life years (QALY) and events of cirrhosis per 1,000 treated patients. Two alternatives were assessed: 1) 12 weeks of TVR plus PR and 2) 24-44 weeks of BOC plus PR. Discount rate 3% and exchange rate (1 USD = 2,6 S/).  RESULTS: 1) Total costs (USD):  TVR plus PR ($56,058), BOC plus PR ($64,536). 2) Medication costs (USD):  TVR plus PR ($47,297), BOC plus PR ($54,649). 3) SVR: TVR plus PR (76%), BOC plus PR (60%). 4) QALY: TVR plus PR (6,02), BOC plus PR (5,87). 5) Cirrhosis per 1,000 treated patients: TVR plus PR (311), BOC plus PR (363). Incremental Cost Effectiveness Ratio (ICER) was negative, showing that 12 weeks of TVR plus PR is a dominant therapy.  CONCLUSIONS: When a DAA is considered, in addition to PR, for previously treated patients, TVR is the preferred choice because of its potential cost-savings versus BOC and incremental health benefits versus BOC.